Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.

Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, Ishikawa T, Abe H, Kato K, Morishita A, Tani J, Okubo T, Nagao M, Iwabu M, Iwakiri K

Diabetes, obesity & metabolism2 Sept 2024Cited by 17 (Europe PMC)

PMID39223865DOI10.1111/dom.15898PepBankPUB-39223865

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studySafety outcome
In patients with MASLD and type 2 diabetes starting oral semaglutide, nausea (grade 1-2) occurred in 23 patients (28.8%).
In plain wordsIn people with fatty liver disease and type 2 diabetes starting oral semaglutide, mild nausea occurred in 23 of 80 patients.
Peptide
Semaglutide
Outcome
Not applicableNausea
Study
n = 80
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Measurements
Nausea
28.8%
oral semaglutide
Source sentences
Summary
The most common adverse events were Grades 1-2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%)
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386512
02HumanObservational studySafety outcome
In patients with MASLD and type 2 diabetes starting oral semaglutide, dyspepsia (grade 1-2) occurred in 12 patients (15.0%).
In plain wordsIn people with fatty liver disease and type 2 diabetes starting oral semaglutide, mild dyspepsia occurred in 12 of 80 patients.
Peptide
Semaglutide
Outcome
Not applicableDyspepsia
Study
n = 80
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Measurements
Dyspepsia
15%
oral semaglutide
Source sentences
Summary
The most common adverse events were Grades 1-2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%), dyspepsia (12, 15.0%)
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386513
03HumanObservational studySafety outcome
In patients with MASLD and type 2 diabetes starting oral semaglutide, appetite loss (grade 1-2) occurred in 4 patients (5.0%).
In plain wordsIn people with fatty liver disease and type 2 diabetes starting oral semaglutide, mild appetite loss occurred in 4 of 80 patients.
Peptide
Semaglutide
Outcome
Not applicableAppetite loss
Study
n = 80
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Measurements
Appetite loss
5%
oral semaglutide
Source sentences
Summary
The most common adverse events were Grades 1-2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%), dyspepsia (12, 15.0%) and appetite loss (4, 5.0%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386514
04HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, body weight improved at 48 weeks of oral semaglutide compared with baseline.
In plain wordsIn people with fatty liver disease and type 2 diabetes, body weight improved after 48 weeks of oral semaglutide compared with the start.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 48 weeks
Study
n = 70
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386501
05HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, liver enzymes improved at 48 weeks of oral semaglutide compared with baseline.
In plain wordsIn people with fatty liver disease and type 2 diabetes, liver enzymes improved after 48 weeks of oral semaglutide compared with the start.
Peptide
Semaglutide
Outcome
DecreaseLiver enzymes at 48 weeks
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386502
06HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, the lipid profile improved at 48 weeks of oral semaglutide compared with baseline.
In plain wordsIn people with fatty liver disease and type 2 diabetes, blood lipids improved after 48 weeks of oral semaglutide compared with the start.
Peptide
Semaglutide
Outcome
Direction not reportedLipid profile at 48 weeks
Study
n = 70
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386503
07HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, glycaemic control improved at 48 weeks of oral semaglutide compared with baseline.
In plain wordsIn people with fatty liver disease and type 2 diabetes, blood sugar control improved after 48 weeks of oral semaglutide compared with the start.
Peptide
Semaglutide
Outcome
DecreaseGlycaemic control at 48 weeks
Study
n = 70
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386504
08HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, controlled attenuation parameter values decreased from baseline to 48 weeks of oral semaglutide.
In plain wordsIn people with fatty liver disease and type 2 diabetes, a liver fat measure fell over 48 weeks of oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseControlled attenuation parameter (liver steatosis)
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Controlled attenuation parameter values significantly decreased from baseline to 48 weeks (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386505
09HumanObservational studyMechanism
In patients with MASLD and type 2 diabetes on oral semaglutide, changes in alanine aminotransferase correlated with changes in body weight.
In plain wordsIn people with fatty liver disease and type 2 diabetes on oral semaglutide, liver enzyme changes were linked to body weight changes.
Peptide
Semaglutide
Outcome
Not applicableCorrelation of ALT change with body weight change
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Changes in alanine aminotransferase concentrations (r = 0.37, p < 0.01) and controlled attenuation parameter values (r = 0.44, p < 0.01) were significantly correlated with changes in body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386506
10HumanObservational studyMechanism
In patients with MASLD and type 2 diabetes on oral semaglutide, changes in controlled attenuation parameter values correlated with changes in body weight.
In plain wordsIn people with fatty liver disease and type 2 diabetes on oral semaglutide, changes in a liver fat measure were linked to body weight changes.
Peptide
Semaglutide
Outcome
Not applicableCorrelation of controlled attenuation parameter change with body weight change
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Changes in alanine aminotransferase concentrations (r = 0.37, p < 0.01) and controlled attenuation parameter values (r = 0.44, p < 0.01) were significantly correlated with changes in body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386507
11HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, type IV collagen 7S decreased from baseline to 48 weeks of oral semaglutide.
In plain wordsIn people with fatty liver disease and type 2 diabetes, a liver scarring marker fell over 48 weeks of oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseType IV collagen 7S
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386508
12HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, Wisteria floribunda agglutinin-positive Mac-2-binding protein decreased from baseline to 48 weeks of oral semaglutide.
In plain wordsIn people with fatty liver disease and type 2 diabetes, a liver scarring marker fell over 48 weeks of oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseWisteria floribunda agglutinin-positive Mac-2-binding protein
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386509
13HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, the fibrosis-4 index decreased from baseline to 48 weeks of oral semaglutide.
In plain wordsIn people with fatty liver disease and type 2 diabetes, a liver scarring score fell over 48 weeks of oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFibrosis-4 index
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386510
14HumanObservational studyEfficacy outcome
In patients with MASLD and type 2 diabetes, liver stiffness decreased from baseline to 48 weeks of oral semaglutide.
In plain wordsIn people with fatty liver disease and type 2 diabetes, liver stiffness fell over 48 weeks of oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLiver stiffness measurement
Study
n = 70
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oral · 48 weeksAs given in this study (human).
Source sentences
Summary
Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a single-arm, multicentre, prospective study.
Summary · context
Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis.
Report a problemFND-3922386511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.

Summary

Results from this study14

Version history

Subjects

Publication types

MeSH terms

Keywords